Global Patent Index - EP 2903643 A4

EP 2903643 A4 20160615 - TREATMENT OF PSYCHIATRIC CONDITIONS

Title (en)

TREATMENT OF PSYCHIATRIC CONDITIONS

Title (de)

BEHANDLUNG VON PSYCHIATRISCHEN ERKRANKUNGEN

Title (fr)

TRAITEMENT D'AFFECTIONS PSYCHIATRIQUES

Publication

EP 2903643 A4 20160615 (EN)

Application

EP 13843079 A 20131001

Priority

  • US 201261709741 P 20121004
  • US 2013062899 W 20131001

Abstract (en)

[origin: WO2014055541A1] The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-la. Anxiety and other psychiatric conditions are also improved with this treatment.

IPC 8 full level

A61K 39/395 (2006.01); A61P 17/10 (2006.01); A61P 25/00 (2006.01); C07K 16/24 (2006.01)

CPC (source: EP)

A61P 17/02 (2018.01); A61P 17/10 (2018.01); A61P 25/00 (2018.01); A61P 25/22 (2018.01); C07K 16/245 (2013.01); A61K 2039/505 (2013.01)

Citation (search report)

  • [Y] GRAHAME V ET AL: "The psychological correlates of treatment efficacy in acne", DERMATOLOGY AND PSYCHOSOMATICS 2002 CH, vol. 3, no. 3, 2002, pages 119 - 125, XP009189887, ISSN: 1422-9196
  • [Y] RUBINOW D R ET AL: "Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 17, no. 1, 1 July 1987 (1987-07-01), pages 25 - 32, XP025650586, ISSN: 0190-9622, [retrieved on 19870701], DOI: 10.1016/S0190-9622(87)70166-2
  • [Y] YESIM KAYMAK ET AL: "Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents", INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 48, no. 1, 1 January 2009 (2009-01-01), UK, pages 41 - 46, XP055269926, ISSN: 0011-9059, DOI: 10.1111/j.1365-4632.2009.03806.x
  • [Y] CHARLES A. DINARELLO ET AL: "Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases", NATURE REVIEWS DRUG DISCOVERY, vol. 11, no. 8, 1 August 2012 (2012-08-01), pages 633 - 652, XP055051238, ISSN: 1474-1776, DOI: 10.1038/nrd3800
  • [YA] ROSSI SILVIA ET AL: "Interleukin-1 beta Causes Anxiety by Interacting with the Endocannabinoid System", JOURNAL OF NEUROSCIENCE, vol. 32, no. 40, 3 October 2012 (2012-10-03), pages 13896 - 13905, XP002757320, ISSN: 0270-6474
  • [A] K. SZABÓ ET AL: "Interleukin-1A +4845(G> T) polymorphism is a factor predisposing to acne vulgaris", TISSUE ANTIGENS., vol. 76, no. 5, 11 November 2010 (2010-11-11), DK, pages 411 - 415, XP055270523, ISSN: 0001-2815, DOI: 10.1111/j.1399-0039.2010.01530.x
  • [T] CARRASCO DANIEL ET AL: "An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity", JOURNAL OF DRUGS IN DERMATOLOGY, STRATEGIC COMMUNICATION IN DERMATOLOGY, NEW YORK, NY, US, vol. 14, no. 6, 1 June 2015 (2015-06-01), pages 560 - 564, XP009188540, ISSN: 1545-9616

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2014055541 A1 20140410; AU 2013327498 A1 20150402; AU 2013327498 B2 20180628; CA 2886757 A1 20140410; CA 2886757 C 20220405; CN 104684581 A 20150603; EP 2903643 A1 20150812; EP 2903643 A4 20160615; JP 2015531396 A 20151102; JP 2020143133 A 20200910; JP 2022177132 A 20221130; JP 6750941 B2 20200902; KR 20150064091 A 20150610

DOCDB simple family (application)

US 2013062899 W 20131001; AU 2013327498 A 20131001; CA 2886757 A 20131001; CN 201380050428 A 20131001; EP 13843079 A 20131001; JP 2015535741 A 20131001; JP 2020090717 A 20200525; JP 2022144756 A 20220912; KR 20157009988 A 20131001